Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
R. Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S. White, Carina Ittrich, Claudia Diefenbach, Klaus B. Rohr, Moisés Selman, Toby M. Maher · 2024
Read Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis by R. Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S. White, Carina Ittrich, Claudia Diefenbach, Klaus B. Rohr, Moisés Selman, Toby M. Maher (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647937.txt.
Description
A peer-reviewed research article from Europe PMC (2024). BackgroundBiomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK trial.MethodsSubjects with IPF were randomised 1:2 to receive nintedanib 150 mg twice daily or placebo for 12 weeks, after which all patients received open-label nintedanib for 40 weeks.
Catalog record
| CREATOR | R. Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S. White, Carina Ittrich, Claudia Diefenbach, Klaus B. Rohr, Moisés Selman, Toby M. Maher |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |